Cargando…
siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma
Delivery is a very important concern for therapeutic applications of siRNA. In this study, we have used chitosan-coated poly(isobutylcyanoacrylate) nanoparticles to deliver siRNA with a complementary sequence to the fusion oncogene ret/PTC1. By screening the mRNA junction we have selected a potent s...
Autores principales: | de Martimprey, Henri, Bertrand, Jean-Remi, Fusco, Alfredo, Santoro, Massimo, Couvreur, Patrick, Vauthier, Christine, Malvy, Claude |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2248757/ https://www.ncbi.nlm.nih.gov/pubmed/18079153 http://dx.doi.org/10.1093/nar/gkm1094 |
Ejemplares similares
-
siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma
por: de Martimprey, Henri, et al.
Publicado: (2008) -
Effects of siRNA on RET/PTC3 Junction Oncogene in Papillary Thyroid Carcinoma: From Molecular and Cellular Studies to Preclinical Investigations
por: Ali, Hafiz Muhammad, et al.
Publicado: (2014) -
RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma
por: Romei, Cristina, et al.
Publicado: (2012) -
Radiation exposure, young age, and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer: a meta-analysis
por: Su, Xuan, et al.
Publicado: (2016) -
RET/PTC and CK19 Expression in Papillary Thyroid Carcinoma and Its Clinicopathologic Correlation
por: Shin, Eunah, et al.
Publicado: (2005)